A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
A phase 3 trial of Ifinatamab deruxtecan, Docetaxel, Prednisone in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) is a phase 3 interventional study registered as NCT06925737 by Merck Sharp & Dohme LLC, with 1440 participants planned, started 2025-05-13 and due to reach its primary completion in 2028-06-26. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Prednisone, Rescue Medication. Conditions listed: Prostate Cancer, Prostatic Neoplasms. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Shares Ifinatamab deruxtecan, Docetaxel, Merck & Co. (MSD).
- TrialA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Shares Ifinatamab deruxtecan, Docetaxel, Merck & Co. (MSD), Prostate cancer.
- TrialA Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Shares Prednisone, Docetaxel, Prostate cancer.
- TrialA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Prednisone, Docetaxel, Prostate cancer.
- TrialSubstudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Shares Prednisone, Docetaxel, Merck & Co. (MSD), Prostate cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).
- TrialStudy of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).
- TrialA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Shares Ifinatamab deruxtecan, Merck & Co. (MSD).